Sign up to save your podcasts
Or
Share Case study: GLP-1 RA in practice | With Dr Deborah Wexler
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Case study: GLP-1 RA in practice | With Dr Deborah Wexler
Another special episode looking at an in-depth case study, this time regarding use of GLP-1 receptor agonists. Joining us to discuss the case is Dr Deborah Wexler, Associate Professor of Medicine at Harvard Medical School, Boston MA, USA, who was a co-author of the ADA-EASD Consensus Statement on Management of Hyperglycemia in Type 2 Diabetes.
For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn.
Disclosures:
Dr Deborah Wexler declares the following:
Member of data monitoring committee for SOUL and FLOW trials studying semaglutide, a GLP-1 receptor agonist: Novo Nordisk
All conflicts of interest have been mitigated prior to this activity.
Funding statement:
This independent educational activity is supported by educational grants from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.
View all episodes
By Liberum IME
5
11 ratings
Another special episode looking at an in-depth case study, this time regarding use of GLP-1 receptor agonists. Joining us to discuss the case is Dr Deborah Wexler, Associate Professor of Medicine at Harvard Medical School, Boston MA, USA, who was a co-author of the ADA-EASD Consensus Statement on Management of Hyperglycemia in Type 2 Diabetes.
For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn.
Disclosures:
Dr Deborah Wexler declares the following:
Member of data monitoring committee for SOUL and FLOW trials studying semaglutide, a GLP-1 receptor agonist: Novo Nordisk
All conflicts of interest have been mitigated prior to this activity.
Funding statement:
This independent educational activity is supported by educational grants from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.